

# Attastic

**Patients' Portal to Cutting-edge  
Disease Research and Technologies**

Frontiers

[New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022](#)



About ALS Treatments News Columns ALS roadmap a progressive neurodegenerative disorder that affects the brain and spinal cord.

Make a plan ALS roadmap: From early treatment to informed choices

Featured Articles

October 9, 2024 News by Katherine Poinsatte

Neuvivo requests FDA approval of ALS treatment NP001

Neuvivo has filed an application with the U.S. Food and Drug Administration for an investigational therapy NP001 (sodium chlorite) to treat amyotrophic lateral sclerosis. The application comes on the heels of combined data from Phase 2a (NC

READ MORE



October 8, 2024 News FGF4 shows benefits for motor neurons. A growth factor called FGF4 — star-shaped cells in the brain — is overly reactive in amyotrophic lateral sclerosis and doesn't stop motor neurons from dying. The researchers

ALS Clinical Trials and Research

**Ken Menkhaus**  
22 September at 00:47  
The NIH announced the FY 2024 part of the Act for ALS. 200 spot https://reporter.nih.gov/project-d

REPORTER.NIH.GOV  
RePORT > RePORTER

10  
Like

View more comments

**Nadia Sethi** Admin Top contributor  
And also interesting that Wide Trial is involved. Years ago a group of us were told by advocacy leadership that Wide Trial was "nothing" and not legitimate.  
2w Like Reply Share

Drug advances to clinical trials for ALS



ALS Forum » ALS Topics » ALS Research & Treatments

573 pages: [1] 2 3 4 5 6 7 ... Last

ALS Research & Treatments				
Topics	Replies	Views	Last Post	
[ Sticky ] <a href="#">IMPORTANT - Your Lab Abnormalities Needed</a> - [ Goto Page: 1 ... 8, 9, 10 ]	182	145,679	1/13/2023 4:19:10 PM by KimB	
[ Sticky ] <a href="#">Abbreviations used in ALS and ALS Research</a>	5	19,488	1/9/2023 1:19:13 PM by henryham897	
[ Sticky ] <a href="#">Newly Diagnosed? New to the forum? – Please read here first</a> - [ Goto Page: 1 ... 3, 4, 5 ]	84	141,438	1/6/2020 12:20:08 AM by David Hicks	
[ Moved ] <a href="#">Bitcoin (and why it matters here)</a>	0	0	No Posts	
<a href="#">Artificial Intelligence and ALS</a>	4	454	Today at 9:34:08 AM by gocurcama	
<a href="#">Oral Sodium Chlorite</a> - [ Goto Page: 1 ... 205, 206, 207 ]	4,134	1,300,663	Yesterday at 10:21:58 AM by mdrdan	

# The Problem

Patients with devastating diseases are **eager** to learn about research progress, but it is:



Hard to access



Difficult to understand



Misinformation prevalent




Not patient-centric



# Our Solution

A one-stop platform providing comprehensive, easy-to-understand, and engaging disease research information and tools for patients



01

Tailored for patients

02

Evidence-based content

03

Comprehensive resources

04

Engaging community

# Product Overview

August 30, 2024

Organization

## ALS Biopharma Advances Research in ALS Therapies

ALS Biopharma is making significant strides in the development of new therapies for Amyotrophic Lateral Sclerosis (ALS). This progressive neurodegenerative disease affects nerve cells in the brain and spinal cord.

### ALS Risk Factors: An Evidence-Based Self-Assessment Tool

This tool presents a compilation of potential risk and protective factors associated with ALS as identified in published scientific literature. This self-assessment tool is designed to help individuals explore their potential

## Clinical Trial Exploring the Potential Benefits of Ranolazine for ALS

AI

NOT\_YET\_RECRUITING INTERVENTIONAL

Fairway, United States

Start Date: December 01, 2024

Completion Date: December 01, 2026

Age Eligibility: min 18.0 years

Gender: ALL

Sponsored by Dr. Jeffrey Statland and supported by the ALS Association, this study aims to assess the safety and effectiveness of ranolazine in reducing muscle cramps and improving overall quality of life for ALS patients. The trial is expected to begin recruiting participants in December 2024.


The study, identified as NCT06527222, is classified as an interventional Phase 2 trial. It will involve an estimated 72 participants, all of whom must be at least 18 years old and can be of any gender. The trial will take place at the University of Kansas Medical Center in Fairway, Kansas.

Participants will be randomly assigned to receive either ranolazine or a placebo, with the study designed to ensure that neither the participants nor the healthcare providers know who is receiving which treatment. This method, known as quadruple masking, helps ensure that the

Ask



## Personalized Content



## Diverse Information



## Miscellaneous Tools



## Compassionate Design



Attastic

For You

News

Engage

Forum



May 24, 2024

### Study Explores Potential of Stem Cell-Derived Extracellular Vesicles in ALS Treatment

A study by Sylwia Dabrowska and her team at the University of Verona has investigated the effects of extracellular vesicles derived from adipose mesenchymal stem cells on microglial activation in a cellular model of Amyotrophic Lateral Sclerosis (ALS). Published on May 24, 2024, in the *International Journal of...*

👁 370 👍 2 💬 81

April 01, 2020

### One Study Explores Potential Benefits of I-Serine in ALS/MND Research


A study published in the *Journal of Neuropathology and Experimental Neurology* on April 1, 2020, by David A

Start from one disease.

A lot more features are coming!

Rapid iteration based on user feedback.

# Application Example



Facebook Group for ALS patients who believe they just had an infection

# Application Example

## ALS Risk Factors: An Evidence-Based Self-Assessment Tool

This tool presents a compilation of potential risk and protective factors associated with ALS as identified in published scientific literature. This self-assessment tool is designed to help individuals explore their potential exposures to these factors. Users can review various environmental factors, daily items, and activities potentially associated with ALS risk. Each factor is linked to relevant peer-reviewed research papers, providing the scientific basis for its inclusion. It's important to note that the presence of these factors does not necessarily indicate causation or guarantee the development of ALS. This tool aims to provide evidence-based information to support patient awareness and facilitate discussions with healthcare providers. Users should interpret the results in consultation with medical professionals, as the complex interplay of genetic and environmental factors in ALS development remains an active area of research.

**Risk Factor** **Pesticides** References ▶


Evidence Level: ★★ ★

Agricultural work
Home gardening with pesticide use
Proximity to pesticide-treated areas

**Risk Factor** **Electromagnetic Fields** References ▶

Evidence Level: ★★ ★

Prolonged use of high-powered electrical devices
Living near power lines or cell towers



# Market Opportunity

## Statistics of 19 example diseases

Disease	Number of Patients	5-Year Survival (%)
Pancreatic cancer	952,000	9
Lung cancer	4,109,000	19
Liver cancer	637,000	20
Acute myeloid leukemia	224,000	29
Glioblastoma (brain cancer)	224,000	6
Esophageal cancer	357,000	20
Ovarian cancer	1,001,000	49
Multiple myeloma	462,000	54
Mesothelioma	14,000	10
Gallbladder cancer	91,000	19
Amyotrophic lateral sclerosis	112,000	20
Huntington's disease	420,000	Life expectancy 15-18y
Parkinson's disease	9,240,000	60-80
Alzheimer's disease	1,344,000	60-80
Heart failure	161,000	50
End-stage renal disease	14,000,000	52-60
Spinal cord injury	1,190,000	Chronic, progressive
Muscular dystrophies	700,000	Varies, progressive
Sickle cell disease	1,400,000	Life expectancy ~48y
<b>Total</b>	<b>36.6 million</b>	

Over 100 million affected by devastating diseases!

# Business Model



Freemium Model



Selling cutting-edge products



Advertising Revenue



Agency/Consulting Services



# Competitive Edge



**End-to-End Platform**



**Aggressive AI Utilization**



**10X Cheaper & Faster**



**Deep User Insight**



# JOIN US

## CONTACT US



[info@attastic.com](mailto:info@attastic.com)



<https://www.attastic.com>



Sydney & Melbourne, Australia

